Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab

Cetuximab-based chemoimmunotherapy has been the standard of care for recurrent or metastatic squamous cell carcinoma of the head and neck (r/m SCCHN) for more than a decade. To date, no predictive or prognostic biomarkers have been established to further guide the systemic treatment with cetuximab-b...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Michael Pogorzelski, Thomas Hilser, Saskia C. Ting, Benjamin Kansy, Thomas C. Gauler, Martin Stuschke, Kurt W. Schmid, Stephan Lang, Viktor Grünwald, Martin Schuler, Stefan Kasper
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-05-01
Subjects:	cetuximab head and neck cancer prognostic markers predictive markers systemic treatment resistance mechanism
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.635096/full